Characteristics and treatment of Adefovir Dipivoxil combined with Lamivudine in the treatment of renal damage caused by chronic hepatitis B and cirrhosis
LI Xinwen1 FAN Yuchen2 XING Yanqing1 LU Yujuan1 HAN Liyan2 ZHANG Xiuhua1
1.Department of Infectious Diseases, Zibo Central Hospital, Shandong Province, Zibo 255036, China;
2.Department of Hepatology, Qilu Hospital of Shandong University, Shandong Provence, Ji′nan 250015, China
Abstract：Objective To observe the clinical characteristics of Adfovir Dipivoxil (ADV) combined with Lamivudine (LAM) in the treatment of chronic hepatitis B (CHB) and liver cirrhosis (LC) patients with renal hypophosphatemia and other adverse reactions, and to explore the efficacy of Entecavir (ETV) treatment. Methods From January 2012 to March 2018, patients with CHB and LC (Child-Pugh A grade) who were treated with LAM and ADV combined therapy (add-on scheme) after drug resistance in Zibo Central Hospital of Shandong Province were selected for routine examination. If adverse renal reactions such as hypophosphatemia were found, ADV and LAM were discontinued in time. Patients with mild or moderate CHB were selected as group A and replaced with ETV 0.5. Mg/d. Patients with severe CH B and LC were treated with ETV 1.0 mg/d as group B. Wilcoxon sign rank sum test of paired data was used for statistical analysis. Results Renal damage such as hypophosphatemia occurred after 63 (49, 71) months of add-on regimen treatment, and the biochemical indexes and symptoms gradually improved after ETV treatment. There were significant differences in blood scales and eGFR between the two groups after 6 months of drug change (P < 0.05). There was no significant difference in blood phosphorus and eGFR between the two groups before and after drug change (P > 0.05). Blood HBV DNA was still below the detection limit in all patients after dressing change. Conclusion Patients with CHB and HBV-related liver cirrhosis may develop hypophosphatemia and other adverse reactions after a long-term add-on therapy. Switching to ETV can reduce adverse effects and maintain the efficacy in inhibiting HBV replication.
李新文1 范玉琛2 邢延清1 鲁玉娟1 韩利岩2 张秀华1. 阿德福韦酯联合拉米夫定治疗慢性乙肝和肝硬化致肾损害的特点及处理探讨[J]. 中国医药导报, 2019, 16(20): 164-167.
LI Xinwen1 FAN Yuchen2 XING Yanqing1 LU Yujuan1 HAN Liyan2 ZHANG Xiuhua1. Characteristics and treatment of Adefovir Dipivoxil combined with Lamivudine in the treatment of renal damage caused by chronic hepatitis B and cirrhosis. 中国医药导报, 2019, 16(20): 164-167.
[1] European Association for the Study of the Liver. EASL clinical practice guidelines：management of chronic hepatitis B [J]. J Hepatol，2009，50：227-242.
[2] Tanaka M，Suzuki F，Seko Y，et al. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B [J]. J Gastroenterol，2014，49（3）：470-480.
[3] Kim YJ，Cho HC，Sinn DH，et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients [J]. J Gastroenterol Hepatol，2012，27（2）：306-312.
[4] Yamamoto T，Maruyama Y，Ohashi N，et al. Hypophosphatemia predicts a failure to recover from adefovir-related renal injury after dose reduction in lamivudine-resistant hepatitis B patients [J]. Hepatol Res，2017，47（12）：1272-1281.
[5] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年版）[J].中华肝脏病杂志，2015，23（12）：888-905.
[6] 中华医学会传染病与寄生虫病学分会、肝病学分会联合修定.病毒性肝炎防治方案[J].中华肝脏病杂志，2000，8（6）：324-326.
[7] Levey AS，Stevens LA，Schmid CH，et al. A New Equation to Estimate Glomerular Filtration Rate [J]. Ann Intern Med，2009 May 5，150（9）：604-612.
[8] Izzedine H，Hulot JS，Launay-Vacher V，et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B：two double-blind，randomized，placebo-controlled studies [J]. Kidney Int，2004，66（3）：1153-1158
[9] 刘秋霞，王磊，刘峰.慢性HBV感染患者长期服用阿德福韦酯与肾性低磷血症的相关因素[J].山东大学学报：医学版，2017，55（7）：73-78.
[10] 田敬华，何艳群，马小艳，等.慢性乙型肝炎患者在阿德福韦酯治疗期间的肌酐和血磷水平变化 [J].中华肝脏病杂志，2013，21（3）：239-240.
[11] 何顺梅，张尧，吕朝阳，等.ADV致Fanconi综合征并继发低磷性骨软化症4例[J].复旦学报：医学版，2014，41（3）：374-379.
[12] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection [J]. J Hepatol， 2017，67（2）：370-398.
[13] Terrault NA，Lok ASF，McMahon BJ，et al. Update on prevention， diagnosis， and treatment of chronic hepatitis B：AASLD 2018 hepatitis B guidance [J]. Hepatology，2018，67（4）：1560-1599.
[14] Kayaaslan B，Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B [J].World J Hepatol，2017， 9（5）：227-241.
[15] Tsai MC，Chen CH，Tseng PL，et al. Comparison of renal safety and efficacy of telbivudine， entecavir and tenofovir treatment in chronic hepatitis B patients：real world experience [J]. Clin Microbiol Infect，2016，22（1）：95.e1-95.e7.
[16] Gara N，Zhao X，Collins MT. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B [J]. Aliment Pharmacol Ther，2012，35（11）：1317-1325.
[17] Lian JS，Zhang XL，Lu YF，et al. Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety [J]. Int J Med Sci，2019，16（1）：17-22.
[18] 赖玺杰，连江山，陈涧阳，等.拉米夫定和阿德福韦酯初始联合治疗慢性乙型肝炎和乙型肝炎肝硬化患者替换为恩替卡韦单药治疗的疗效和安全性观察[J].中华肝脏病杂志，2018，26（2）：113-118.
[19] Ze E，Baek EK，Lee JJ，et al. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B：combined lamivudine and adefovir，and 1mg entecavir [J]. Clin Mol Hepatol，2014，20（3）：267-273.
[20] Zhang Q，Chen J，Pan M，et al. Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient [J]. Virus Res，2018，255：165-170.
2019, Vol. 16 
京公网安备 11010502046598号